Alivus Life Sciences · NSE: ALIVUS · BSE: 543322
Q4 FY23 results · Jan–Mar 2023
Alivus Life Sciences reported revenue from operations of ₹621.32 crore (up 20.9% from Q4 FY22) and net profit of ₹146.36 crore (up 48.0% from Q4 FY22) for Q4 FY23 (Jan–Mar 2023), on a standalone basis.
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 621.32 | 514.06 | +20.9% | 540.73 | +14.9% |
| Other income | 2.84 | 5.09 | −44.3% | 6.61 | −57.1% |
| Total income | 624.16 | 519.15 | +20.2% | 547.34 | +14.0% |
| Profit before tax | 197.63 | 137.63 | +43.6% | 141.14 | +40.0% |
| Net profit for the period | 146.36 | 98.90 | +48.0% | 104.99 | +39.4% |
| EPS, basic (₹) | 11.94 | 8.07 | +48.0% | 8.57 | +39.3% |
| Net margin (%) | 23.6 | 19.2 | 19.4 |
Standalone
- Filed with BSE
- 29 Apr 2023, 13:03 IST
- Board meeting
- 27 Apr 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Audited
- Source
- XBRL filing on BSE